LGD 4033 is a Selective Androgen Receptor Modulator, known as a SARM. This particular drug was discovered by Ligand Pharmaceuticals in their research and developing focusing on drugs to manage diseases such as MS and Osteoporosis

LGD in a simple context, binds to the androgen receptor of muscle tissue and produces effects similar to anabolic and androgenic steroids, otherwise known as AAS. One distinct advantage of LGD-4033 is the fact is only partially binds to prostate tissue, which AAS do. This can useful in preventing prostate hypertrophy and other AAS related side effects.

SARMS such as LGD-4033 are often employed as performance enhancing substances because their anabolic and androgenic activity is more isolated to muscle and bone, meaning users will experience less androgenic side effects

SARMS such as LGD4033 have gained great popularity in the bodybuilding community, owing to their lack of side effects and potent performance and image enhancing effects.

Users of LGD4033 report significant lean muscle mass, of which official studies back these claims. This SARM is often seen as an excellent tool for steroid users to bridge cycles, to maintain size and muscle mass. While using LGD4033 as a primary drug for bodybuilding, users will often experience increases in strength, muscle mass, vascularity and reduction in adipose tissue.

This SARM is often cited as being an excellent body re-composition tool, because of it’s synergistic fat loss and muscle building effects. When combined with others SARMs such as Ostarine MK2866 the effects can be similar to use of powerful AAS such as Testosterone and Trenbolone.          Combining or known as “stacking” these SARMS can be a powerful and less HPTA suppressive method of gaining muscle and losing fat.

As with many SARMs, side effects are minimal, however, it is still possible to have similar side effects to AAS but on a much less significant level.

The main side effect of LGD4033 is the HPTA suppression. There is contradicting information about this, but studies show that suppression is minimal in comparison to AAS such as Testosterone. A post cycle therapy is recommended for users of any SARM as a precaution, to minimise hormone disruption and maintain lean body mass gained while using this SARM.

LGD 4033 is not liver toxic to any significant degree, such as oral steroids.

This SARM, like others such as Cardinine, promote and dry and vascular look. Rather than a bloated look which is caused by oedema by the use of AAS such as Testosterone and Nandralone.

LGD4033 has been widely noted to cause a significant increase in muscular endurance, this makes it a popular performance enhancing drug for athletes.